THE Therapeutic Goods Administration has issued a safety advisory warning against the use of shingles vaccine Zostavax in patients with compromised immune function.
The alert follows a report of the death of a patient with a pre-existing condition.
Zostavax was included in the National Immunisation Program on 01 Nov 2016 for the prevention of herpes zoster in patients 70 years of age, with a five-year catch-up program also under way for people aged 71-79 years.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Mar 17